Stay updated with breaking news from Grant Pickering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine Franchise -- -- Manufacturing Rights...
-- Company Expects to Initiate VAX-31 Phase 1/2 Study in Healthy Adults This Quarter-- -- Topline Safety, Tolerability and Immunogenicity Results from VAX-31 Phase 1/2 Study Expected in the Second...
By Rob Curran Vaxcyte said Thursday that the Food and Drug Administration cleared its investigational new drug application for a pneumococcal-infection...
-- New Agreement to Establish Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, VAX-24 and VAX-31, in Adult and Pediatric Pop...
-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series...